Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.7 (plasmin)
9,023 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Evidence is presented for the involvement of a number of specific uterine- and conceptus-derived proteins in endometrial differentiation and conceptus or fetal development. These secretory proteins include mitogens (insulin-like growth factor-I and -II, epidermal growth factor, uterine luminal fluid mitogen), binding and transport proteins (uteroferrin, insulin-like growth factor and retinol binding proteins, respectively), protease inhibitors (antileukoproteinase, plasmin/trypsin inhibitor), and trophoblastic specific proteins. Using immunological reagents and specific complementary DNA (cDNA) probes, the tissue origins of several of these proteins have now been identified. In addition, the temporal regulation of messenger RNA (mRNA) production for a number of these proteins has been elucidated. The results suggest that although circulating and locally produced steroid hormones may be involved in regulating the synthetic abilities of these tissues during pregnancy, other, as yet undefined, factors may also mediate these activities. In this paper we present a review of the current knowledge pertaining to the identity, physiological regulation and potential functions of pig maternal and conceptus secretory proteins during pregnancy.
...
PMID:Regulation of uterine and conceptus secretory activity in the pig. 219 44

We have compared the distribution of two of the major secreted proteins of the porcine uterus within the endometrium of ovariectomized pigs which had received hormone replacement therapy for 30 days. The proteins studied, plasmin/trypsin inhibitor (PI) and uteroferrin (Uf), an iron-containing acid phosphatase, were both secreted into the uterine lumen by ovariectomized gilts given progesterone (P4) or P4 and 17 beta-estradiol but not by animals given 17 beta-estradiol alone or corn oil. The two proteins were localized immunocytochemically within the endometrium using an immunoperoxidase procedure. The results confirmed that production of PI and Uf was P4-dependent and demonstrated that the primary site of synthesis of PI was the surface and upper glandular epithelium, while Uf synthesis was confined to the glandular epithelium. A similar localization of PI and of Uf was found in endometrial tissue from pigs at day 13 (late luteal phase) of the estrous cycle. These results suggest that the uterine epithelium of the pig is regionally differentiated with regard to the production of P4-induced proteins.
...
PMID:Differential patterns of secretory protein localization within the pig uterine endometrium. 315 52

The uterus of the pig secretes large amounts of protein in response to progesterone. Estrogen alone has little effect but in combination with progesterone is synergistic at low doses and inhibitory at high doses. The responses of the uterus to progesterone require prolonged hormone treatment and are not immediate. The proteins secreted by the uterus of all species are believed to play some role in the nutritional and developmental support of the conceptuses, particularly during early pregnancy. Such a role is likely to be of greater importance in species such as the pig which possesses a noninvasive, diffuse-type of epitheliochorial placentation. A group of basic polypeptides dominates the uterine secretions of the pig. The best characterized is uteroferrin, a purple colored, iron-containing acid phosphatase which transports iron across the placenta. Three polypeptides which are found associated noncovalently with uteroferrin have been shown to be antigenically closely related to each other and to have arisen from a single precursor polypeptide. Their function is unknown. A family of plasmin/trypsin inhibitors which show sequence homology with bovine pancreatic trypsin inhibitor (aprotinin) has been well characterized and appears to control intrauterine proteolytic events initiated by the conceptuses. Several other proteins secreted in response to progesterone remain to be characterized and functionally defined.
...
PMID:Hormonal control and function of secretory proteins. 345 17

The porcine uterus secretes a group of basic, low molecular weight protease inhibitors under the influence of progesterone, but not estrogen. One of these inhibitors (Mr approximately 14,500) which inhibits trypsin, plasmin, and chymotrypsin, but not other proteases tested, has been purified 10- to 15-fold from uterine secretions of pseudopregnant pigs using Sephadex G-100 chromatography, CM-cellulose ion exchange chromatography, and Sephadex G-50 or Bio-Gel P-10 chromatography. The inhibitor which is relatively heat- and pH-stable forms a 1:1 molar complex with trypsin which is not dissociated in sodium dodecyl sulfate except by boiling. Chymotrypsin appears to bind at the same site on the inhibitor as trypsin. The inhibitor is high in half-cysteine residues and basic amino acids, and appears not to be a glycoprotein. Antiserum has been raised against the purified inhibitor in rabbits and used to test its distribution in pigs using the immunoperoxidase-staining technique on tissue sections. The inhibitor is associated only with the glandular and surface epithelium of the uterus. Endometrial explants from pseudopregnant animals, cultured in presence of L-[3H]leucine, release the inhibitor in radioactive form indicating that it is a uterine product. The antiserum against the inhibitor cross-reacts with at least three other, basic, low molecular weights plasmin/trypsin inhibitors in porcine uterine secretions, suggesting that a family of isoinhibitors exists which may constitute up to 15% of the protein in porcine uterine secretions. The inhibitor(s) appears to coat and to be taken up by the trophoectoderm cells of the elongating blastocyst during pregnancy. It is suggested that the inhibitors may serve to protect the uterus from proteases released by the porcine trophoblast or to prevent degradation of essential macromolecules, such as uteroferrin, which have to be taken up by the conceptus.
...
PMID:Purification and properties of a progesterone-induced plasmin/trypsin inhibitor from uterine secretions of pigs and its immunocytochemical localization in the pregnant uterus. 621 38

The porcine uterus synthesizes a proteinase inhibitor (M(r) 14,000) under the influence of progesterone that is relatively specific for plasmin and trypsin, but that also has weak affinity for chymotrypsin. Several isoforms of this uterine plasmin/trypsin inhibitor were purified by a procedure whose final two steps involved affinity chromatography on immobilized chymotrypsin and cation exchange chromatography. Amino-terminal sequencing showed that at least three of the isoforms were closely related. An oligonucleotide probe based on the protein sequence was used to identify a cDNA that contained an open reading frame coding for a mature protein (M(r) 10,295) of 93 amino acids. The inhibitor had a well defined, but unique, Kunitz domain of 64 residues at its amino terminus that shared 67% sequence identity to bovine pancreatic trypsin inhibitor. Its P1 residue was arginine rather than lysine. Northern analysis showed the presence of a single mRNA species (700 bases) that in adult female pigs appeared to be confined to the uterus. During pregnancy, UPTI mRNA expression was high until Day 30 and decreased significantly thereafter. By contrast, uteroferrin mRNA reached maximal concentrations in late pregnancy. These data are consistent with an earlier hypothesis that the inhibitor serves to neutralize the activities of one or more serine proteinases generated by the proliferating trophoblast during the formation of the noninvasive placenta of the pig.
...
PMID:Purification, characterization, and cDNA cloning of a Kunitz-type proteinase inhibitor secreted by the porcine uterus. 792 61

Objectives were to examine the effects of a single dose (4 mg) of estradiol-17 beta (E2) on blastocyst development around the period of elongation. Proestrus gilts were induced to ovulate with 750 IU of hCG and were mated before ovulation (normal mating, 24 to 32 h post-hCG) or after ovulation had begun (delayed mating, 43 h post-hCG). This difference in time of mating has been demonstrated to result in approximately a 7-h difference in time of blastocyst elongation. Normally and delay-mated gilts were ovariohysterectomized at 278 h post-hCG or injected with E2 or vehicle (corn oil) at 278 h and then ovariohysterectomized at 290 h post-hCG (five or six gilts per group). Blastocyst size was measured and concentrations of E2, retinol, uteroferrin, insulin-like growth factor-I (IGF-I), uterine plasmin/trypsin inhibitor (UPTI) and protein in uterine flushings were quantified. Blastocyst size and components of uterine flushings did not differ (P > 0.05) between normally and delay-mated gilts at 278 h post-hCG. However, at 290 h post-hCG, normally mated gilts had larger (P < 0.01) blastocysts (small spheres to filamentous) and their flushings tended to contain less (P < 0.07) amounts of retinol than those of delay-mated gilts whose blastocysts ranged from small spheres to ovoidals. Normally mated gilts receiving E2 at 278 h had smaller (P < 0.01) blastocysts and less (P < 0.05) amounts of retinol at 290 h post-hCG than gilts receiving vehicle. Conversely, delay-mated gilts treated with E2 or vehicle did not differ (P > 0.05) in blastocyst size and amounts of components of uterine flushings at 290 h post-hCG. Normally mated gilts treated with vehicle had litters in the process of elongating at 290 h post-hCG. Mean blastocyst size (P < 0.001) and amounts of components of uterine flushings (except for IGF-I) in these gilts were greater (P < 0.05, UPTI = 0.06) than in normally mated gilts at 278 h post-hCG, whose blastocysts were spherical. Among gilts not treated with E2 (278 h and 290 h pooled), mean blastocyst size was positively correlated (P < 0.05) with amounts of retinol, E2, uteroferrin and total protein. Results indicated that a single dose of E2 given before elongation altered blastocyst development depending on how close blastocysts were to onset of elongation at the time of E2 treatment.
...
PMID:Short-term effects of exogenous estradiol-17 beta on blastocyst development during the period of elongation in swine. 923 12

The plasminogen/plasmin proteolytic cascade plays an important role in extracellular matrix remodeling. The presence of the two plasminogen activators (PAs), tissue-type plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA), and their inhibitor type 1 (PAI-1) in bone cells, suggests a role in one or more aspects of bone resorption such as osteoclast formation, mineral dissolution, and degradation of the organic matrix. These different processes were assayed in vitro using cells derived from mice with either tPA (tPA-/-), uPA (uPA-/-), PAI-1 (PAI-1-/-) inactivation or with a combined inactivation (tPA-/-:uPA-/-) and compared with wild-type mice (WT). First, osteoclast formation, assessed by investigating the number and characteristics of tartrate-resistant acid phosphatase-positive multinucleated cells formed in cocultures of primary osteoblasts and bone marrow cells treated with 1alpha,25-dihydroxyvitamin D3, was not different between the different cell types. Second, dentine resorption, an assay for osteoclast activity, was not affected by the combined deficiency of both tPA and uPA. Finally, the ability to degrade nonmineralized bone-like matrix was however, significantly reduced in tPA-/-:uPA-/- cells compared with WT cells (28.1 +/- 0.6%, n = 6 vs. 56.4 +/- 3.1%, n = 6, respectively, p < 0.0001). Surprisingly, collagen proteolysis by bone cells was not dependent on the presence of plasmin as suggested by degradation assays performed on type I 3H-collagen films. Taken together, these data suggest that the plasminogen activator/plasmin system is not required for osteoclast formation, nor for the resorption of the mineral phase, but is involved in the removal of noncollagenous proteins present in the nonmineralized bone matrix.
...
PMID:The role of the plasminogen system in bone resorption in vitro. 1035 3